Results 81 to 90 of about 14,793 (172)

Raltegravir: first in class HIV integrase inhibitor

Therapeutics and Clinical Risk Management, 2008
Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj  

Prevalence and associated factors of metabolic syndrome among people living with HIV in a medical center of Northern Taiwan

Scientific Reports
HIV acquisition has been found to be associated with increased risk of cardiometabolic syndrome in the past. In this study, we attempt to delineate the associated factors of metabolic syndrome among persons living with HIV in a single medical center in ...
Chien-An Tu, Chien-Feng Kuo, Chun-Ming Lee, Chang-Pan Liu, Hsiang-Kuang Tseng, Tseng-Yu Huang, Chih-Chen Lin, Hsun Chang, Winter Yu-Ning Lee, Fang-Ju Sun, Zu-Yi Sun, Pei-Ching Lian, Ming-Wei Cheng, Alice Ying-Jung Wu   +13 more
doaj   +1 more source

Isolation of New Chemical Modulators of the Interaction Between HIV-1 Integrase and the Cellular Restriction Factor GCN2

Viruses
Integrase is a key protein during HIV-1 replication as it catalyzes the integration of viral DNA into the host DNA. After several decades of research, highly potent and selective active site inhibitors have emerged.
Chloé Torres, Floriane Lagadec, Eugenia Basyuk, Patricia Recordon-Pinson, Mathieu Métifiot   +4 more
doaj   +1 more source

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

HIV/AIDS: Research and Palliative Care, 2014
Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency
Pandey KK
doaj  

From protease inhibitors to integrase strand transfer inhibitors: the evolution of HIV drug resistance management

Zhongguo linchuang yanjiu
Antiretroviral therapy (ART) has significantly improved the prognosis of HIV/AIDS patients and has become an important global strategy for the prevention and control of AIDS.
HU Zhiliang, YANG Yongfeng
doaj   +1 more source

Update on Adverse Effects of HIV Integrase Inhibitors. [PDF]

Curr Treat Options Infect Dis, 2019
Kolakowska A, Maresca AF, Collins IJ, Cailhol J.   +3 more
europepmc   +1 more source

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. [PDF]

Clin Pharmacokinet, 2019
van der Galiën R, Ter Heine R, Greupink R, Schalkwijk SJ, van Herwaarden AE, Colbers A, Burger DM.   +6 more
europepmc   +1 more source

Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. [PDF]

Viruses, 2018
Charpentier C, Descamps D.
europepmc   +1 more source

Treatment of HIV Infections with HIV Integrase Inhibitors. [PDF]

ACS Med Chem Lett, 2017
Abdel-Magid AF.
europepmc   +1 more source

Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors. [PDF]

Viruses
Choudhuri I, Olvera JG, Biswas A, Haldane A, Levy RM, Lyumkis D.   +5 more
europepmc   +1 more source